Public Sector Pension Investment Board Boosts Holdings in Zoetis Inc. $ZTS

Public Sector Pension Investment Board grew its position in Zoetis Inc. (NYSE:ZTS) by 12.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,614 shares of the company’s stock after acquiring an additional 4,337 shares during the quarter. Public Sector Pension Investment Board’s holdings in Zoetis were worth $5,650,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in ZTS. North Star Asset Management Inc. raised its holdings in shares of Zoetis by 4.9% in the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock worth $225,000 after buying an additional 67 shares during the period. Moment Partners LLC grew its position in Zoetis by 3.2% in the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after acquiring an additional 72 shares during the last quarter. CVA Family Office LLC increased its stake in Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after purchasing an additional 74 shares during the period. Bank of Nova Scotia Trust Co. lifted its position in shares of Zoetis by 4.6% during the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after purchasing an additional 74 shares during the last quarter. Finally, RWA Wealth Partners LLC lifted its position in shares of Zoetis by 2.7% during the second quarter. RWA Wealth Partners LLC now owns 2,852 shares of the company’s stock worth $445,000 after purchasing an additional 76 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

NYSE ZTS opened at $129.17 on Thursday. The company has a market cap of $54.53 billion, a PE ratio of 21.46, a P/E/G ratio of 1.92 and a beta of 0.96. The firm’s 50 day moving average price is $125.01 and its 200-day moving average price is $135.02. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the firm posted $1.40 earnings per share. Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.